MCID: YLL002
MIFTS: 61

Yellow Fever

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Yellow Fever

MalaCards integrated aliases for Yellow Fever:

Name: Yellow Fever 12 76 53 59 55 3 44 15 73
Jungle Yellow Fever 12 73
Urban Yellow Fever 12 73
Yf 53 59
Sylvatic Yellow Fever 12
Yellow Fever, Sylvan 12
Bronze John 59
Yellow Jack 59

Characteristics:

Orphanet epidemiological data:

59
yellow fever
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


Summaries for Yellow Fever

CDC : 3 The yellow fever virus is found in tropical and subtropical areas of Africa and South America. The virus is spread to people by the bite of an infected mosquito. Yellow fever is a very rare cause of illness in U.S. travelers. Illness ranges from a fever with aches and pains to severe liver disease with bleeding and yellowing skin (jaundice). Yellow fever infection is diagnosed based on laboratory testing, a person’s symptoms, and travel history. There is no medicine to treat or cure infection. To prevent getting sick from yellow fever, use insect repellent, wear long-sleeved shirts and long pants, and get vaccinated.

MalaCards based summary : Yellow Fever, also known as jungle yellow fever, is related to encephalitis and west nile virus, and has symptoms including fever, muscle pain and backache. An important gene associated with Yellow Fever is EIF2AK4 (Eukaryotic Translation Initiation Factor 2 Alpha Kinase 4), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Vaccines and Vitamin A have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and testes, and related phenotypes are renal insufficiency and proteinuria

Disease Ontology : 12 A viral infectious disease that results in infection, has material basis in Yellow fever virus, which is transmitted by Aedes, transmitted by Haemagogus, or transmitted by Sabethes species of mosquitoes. The infection has symptom fever, has symptom muscle pain, has symptom backache, has symptom headache, has symptom shivers, has symptom loss of appetite, has symptom jaundice, and has symptom bleeding from the mouth, nose, eyes or stomach leading to vomitus containing blood.

Wikipedia : 76 Yellow fever is a viral disease of typically short duration. In most cases, symptoms include fever,... more...

Related Diseases for Yellow Fever

Diseases related to Yellow Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
# Related Disease Score Top Affiliating Genes
1 encephalitis 31.1 CCL5 CCR5 RSAD2
2 west nile virus 30.1 CCR5 OAS1 RSAD2
3 dermatitis, atopic 28.3 CCL5 IL17A IL5 TLR9
4 multiple sclerosis 28.0 CCL5 CCR5 IL17A IL5 TLR9
5 malaria 28.0 CCL5 IL17A IL1A IL5 TLR9
6 influenza 28.0 CCL5 IL1A IRF7 RSAD2 TLR9
7 hemorrhagic fever 11.1
8 kyasanur forest disease 10.8
9 whiplash 10.8 CCL5 CCR5
10 respiratory syncytial virus infectious disease 10.7 CCL5 IL5
11 cow milk allergy 10.7 CCR5 IL5
12 chronic eosinophilic pneumonia 10.7 CCL5 IL5
13 apple allergy 10.6 IL5 SCP2
14 gastrointestinal allergy 10.6 CCL5 IL5
15 chronic conjunctivitis 10.6 CCL5 IL5
16 status asthmaticus 10.6 CCL5 IL5
17 kimura disease 10.5 CCL5 IL5
18 chronic nk-cell lymphocytosis 10.5 CCL5 CCR5
19 folliculitis 10.5 CCL5 IL5
20 orofacial granulomatosis 10.4 CCL5 CCR5
21 vernal keratoconjunctivitis 10.4 CCL5 IL5
22 stachybotrys chartarum 10.4 CCL5 IL1A
23 meningococcemia 10.3 CCL5 IL1A
24 oral lichen planus 10.3 CCL5 CCR5 IL1A
25 hepatitis 10.1
26 chikungunya 10.1
27 allergic asthma 10.1 CCL5 IL17A IL5
28 leukoencephalopathy with dystonia and motor neuropathy 10.1
29 dengue virus 10.1
30 st. louis encephalitis 10.1
31 measles 10.1
32 mucocutaneous leishmaniasis 10.1 CCR5 TLR9
33 immune-complex glomerulonephritis 10.0 CCR5 TLR9
34 west nile encephalitis 10.0 OAS1 TLR9
35 aging 10.0
36 japanese encephalitis 10.0
37 hepatitis a 10.0
38 egg allergy 10.0
39 neuronitis 10.0
40 smallpox 10.0
41 hepatitis c virus 10.0 CCR5 IRF7 RSAD2
42 typhoid fever 9.9
43 avoidant personality disorder 9.9 CCL5 CCR5
44 contact dermatitis 9.9 IL17A IL1A IL5
45 tetanus 9.8
46 melanoma 9.8
47 vaccinia 9.8
48 poliomyelitis 9.8
49 viral encephalitis 9.8
50 type i 9.8

Graphical network of the top 20 diseases related to Yellow Fever:



Diseases related to Yellow Fever

Symptoms & Phenotypes for Yellow Fever

Symptoms:

12
  • fever
  • muscle pain
  • backache
  • headache
  • shivers
  • loss of appetite
  • jaundice
  • bleeding from the mouth

Human phenotypes related to Yellow Fever:

59 32 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
2 proteinuria 59 32 frequent (33%) Frequent (79-30%) HP:0000093
3 nephropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0000112
4 photophobia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000613
5 jaundice 59 32 frequent (33%) Frequent (79-30%) HP:0000952
6 lethargy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001254
7 meningitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001287
8 congestive heart failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001635
9 dehydration 59 32 occasional (7.5%) Occasional (29-5%) HP:0001944
10 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
11 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
12 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
13 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
14 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
15 hypothermia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002045
16 malignant hyperthermia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002047
17 gastrointestinal hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0002239
18 headache 59 32 hallmark (90%) Very frequent (99-80%) HP:0002315
19 encephalitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002383
20 hypotension 59 32 occasional (7.5%) Occasional (29-5%) HP:0002615
21 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
22 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
23 spontaneous abortion 59 32 frequent (33%) Frequent (79-30%) HP:0005268
24 cardiorespiratory arrest 59 32 occasional (7.5%) Occasional (29-5%) HP:0006543
25 acute hepatic failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0006554
26 arrhythmia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011675
27 oliguria 59 32 frequent (33%) Frequent (79-30%) HP:0100520
28 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
29 menometrorrhagia 59 32 frequent (33%) Frequent (79-30%) HP:0400008

MGI Mouse Phenotypes related to Yellow Fever:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 IL5 IRF7 RAF1 CCL5 CCR5 RSAD2
2 homeostasis/metabolism MP:0005376 9.93 IL5 IRF7 RAF1 CCR5 RSAD2 SCP2
3 immune system MP:0005387 9.73 IRF7 RAF1 CCL5 CCR5 RSAD2 EIF2AK4
4 liver/biliary system MP:0005370 9.1 IL5 RAF1 CCR5 SCP2 EIF2AK4 FGA

Drugs & Therapeutics for Yellow Fever

Drugs for Yellow Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 11103-57-4, 68-26-8 445354
3
Lactitol Investigational Phase 3 585-86-4 3871
4 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
5 Retinol palmitate Phase 3
6 Micronutrients Phase 3
7 Trace Elements Phase 3
8 Vitamins Phase 3
9 Antioxidants Phase 3
10 Protective Agents Phase 3
11 retinol Nutraceutical Phase 3
12
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
13 tannic acid Approved, Nutraceutical Phase 1, Phase 2
14 Antibodies Phase 2,Phase 1,Not Applicable
15 Immunoglobulins Phase 2,Phase 1,Not Applicable
16 Antimetabolites Phase 2
17 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
18 Hypolipidemic Agents Phase 2
19 Anticholesteremic Agents Phase 2
20 Lipid Regulating Agents Phase 2
21 Anti-Inflammatory Agents Phase 2
22
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251
23
Aluminum sulfate Approved Phase 1 10043-01-3
24
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
25 diuretics Phase 1
26 Rho(D) Immune Globulin Phase 1
27 gamma-Globulins Phase 1
28 Natriuretic Agents Phase 1
29 Immunoglobulins, Intravenous Phase 1
30
Methotrexate Approved 1959-05-2, 59-05-2 126941
31
leucovorin Approved, Nutraceutical 58-05-9 143 6006
32
Folic Acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
33 Folic Acid Antagonists
34 Dermatologic Agents
35 Nucleic Acid Synthesis Inhibitors
36 Vitamin B Complex
37 Immunosuppressive Agents
38 Antirheumatic Agents
39 Antimetabolites, Antineoplastic
40 Folate Nutraceutical
41 Vitamin B9 Nutraceutical

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
2 Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali Completed NCT02286895 Phase 4
3 Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study) Recruiting NCT02555072 Phase 4
4 Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals Recruiting NCT03132311 Phase 4
5 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
6 Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) Active, not recruiting NCT02991495 Phase 4
7 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Unknown status NCT01373281 Phase 3
8 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
9 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3
10 Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) Completed NCT01345240 Phase 3
11 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults Recruiting NCT03342898 Phase 3
12 The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. Active, not recruiting NCT01426243 Phase 3
13 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. Active, not recruiting NCT02699099 Phase 3
14 Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) Completed NCT00982137 Phase 2
15 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
16 The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans Completed NCT01943305 Phase 2
17 Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
18 Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen Completed NCT00436007 Phase 2
19 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
20 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
21 Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants Completed NCT01262872 Phase 2
22 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
23 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
24 Yellow Fever Vaccine on Statin/ Non Statin Subjects Recruiting NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
25 Trial of Yellow Fever Inactivated Vaccine Completed NCT00995865 Phase 1
26 Yellow Fever Virus Vaccine and Immune Globulin Study Completed NCT00254826 Phase 1
27 A Phase I Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers Completed NCT02743455 Phase 1 ISA-720
28 Phase I Study of West Nile Virus Vaccine Completed NCT00300417 Phase 1 VRC-WNVDNA020-00-VP
29 A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. Active, not recruiting NCT02963909 Phase 1
30 Yellow Fever Vaccination Under Low Dose Methotrexate Therapy Unknown status NCT02383680
31 Immunity After Two Doses of Yellow Fever Vaccine Completed NCT02572518
32 Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military Completed NCT03338231
33 Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults Completed NCT00616356
34 Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines Completed NCT01765413 Not Applicable
35 The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination Completed NCT00708630 Not Applicable
36 Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali Completed NCT02311387
37 Evaluation of the Safety & Performance of 2 Intradermal Safety Devices Completed NCT02556047 Not Applicable
38 Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children Completed NCT01391819 Not Applicable
39 The Interaction Between Measles and DTP Vaccination Completed NCT02710045 Not Applicable
40 Yellow Fever Vaccine in Patients With Rheumatic Diseases Recruiting NCT03430388 Not Applicable
41 Yellow Fever Immune Response at Single Cell Resolution Recruiting NCT03458780 Yellow Fever Vaccine
42 Turnover of Antigen Specific Lymphocytes After Immunization With the Yellow Fever Vaccine Recruiting NCT01290055 Not Applicable
43 Immune Responses to Yellow Fever Vaccine Recruiting NCT01244802
44 Human Immune Responses to The Yellow Fever Virus Vaccine Recruiting NCT00694655 Not Applicable
45 Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea Recruiting NCT03541694
46 Cohort of Patients Infected by an Arbovirus Recruiting NCT01099852
47 Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children Recruiting NCT03180359 Not Applicable
48 Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children Active, not recruiting NCT02990182

Search NIH Clinical Center for Yellow Fever

Cochrane evidence based reviews: yellow fever

Genetic Tests for Yellow Fever

Anatomical Context for Yellow Fever

MalaCards organs/tissues related to Yellow Fever:

41
Skin, Liver, Testes, T Cells, Eye, Kidney, Heart

Publications for Yellow Fever

Articles related to Yellow Fever:

(show top 50) (show all 733)
# Title Authors Year
1
A qualitatively validated mathematical-computational model of the immune response to the yellow fever vaccine. ( 29801432 )
2018
2
Yellow Fever - What It Means for Singapore. ( 29911734 )
2018
3
Existing and potential infection risk zones of yellow fever worldwide: a modelling analysis. ( 29398634 )
2018
4
Metagenomic analysis reveals Hepatitis A virus in suspected yellow fever cases in Brazil. ( 29211109 )
2018
5
Evidence for Multiple Sylvatic Transmission Cycles During the 2016-2017 Yellow Fever Virus Outbreak, Brazil. ( 29427798 )
2018
6
Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe. ( 29933925 )
2018
7
Modeling the elevated risk of yellow fever among travelers visiting Brazil, 2018. ( 29961429 )
2018
8
Notes from the Field: Errors in Administration of an Excess Dosage of Yellow Fever Vaccine - United States, 2017. ( 29370153 )
2018
9
Yellow fever vaccination coverage in French Guiana. ( 29303736 )
2018
10
What Does the Future Hold for Yellow Fever Virus? (I). ( 29890711 )
2018
11
The risk of urban yellow fever resurgence in Aedes-infested American cities. ( 29843824 )
2018
12
Zika, dengue and yellow fever viruses induce differential anti-viral immune responses in human monocytic and first trimester trophoblast cells. ( 29331320 )
2018
13
Gold nanoparticles coupled with graphene quantum dots in organized medium to quantify aminoglycoside anti-biotics in yellow fever vaccine after solid phase extraction using a selective imprinted polymer. ( 29960239 )
2018
14
Potential yellow fever epidemics in unexposed populations. ( 29875511 )
2018
15
Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study. ( 29784469 )
2018
16
Yellow fever: a major threat to public health. ( 29407015 )
2018
17
Controversies over the scientific name of the principal mosquito vector of yellow fever virus - expediency versus validity. ( 29757506 )
2018
18
Phylogeny of Yellow Fever Virus, Uganda, 2016. ( 29798746 )
2018
19
Yellow Fever Vaccine for People Living With HIV Infection. ( 29217414 )
2018
20
Stepping up local efforts to stop global spread of yellow fever. ( 29904218 )
2018
21
Gamma-interferon exerts a critical early restriction on replication and dissemination of yellow fever virus vaccine strain 17D-204. ( 29387474 )
2018
22
Development of a non-destructive method for determining protein nitrogen in a yellow fever vaccine by near infrared spectroscopy and multivariate calibration. ( 29751350 )
2018
23
Identification of Dengue and Chikungunya Cases Among Suspected Cases of Yellow Fever in the Democratic Republic of the Congo. ( 29768102 )
2018
24
Places, attitudes and moments during the epidemics: representations of yellow fever and cholera in the city of Buenos Aires, 1867-1871. ( 29898124 )
2018
25
Development of multiplex real time reverse transcriptase PCR assay for simultaneous detection of Zika, Dengue, Yellow Fever and Chikungunya Viruses in a single tube. ( 29979812 )
2018
26
Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models. ( 29231157 )
2018
27
Yellow fever in two unvaccinated French tourists to Brazil, January and March, 2018. ( 29845927 )
2018
28
Modelling the large-scale yellow fever outbreak in Luanda, Angola, and the impact of vaccination. ( 29338001 )
2018
29
Re-evaluate yellow fever risk in Asia-Pacific region. ( 29388975 )
2018
30
Ocular manifestations of emerging arboviruses: Dengue fever, Chikungunya, Zika virus, West Nile virus, and yellow fever. ( 29929827 )
2018
31
International travel between global urban centres vulnerable to yellow fever transmission. ( 29875519 )
2018
32
A natural agonist of mosquito TRPA1 from the medicinal plant Cinnamosma fragrans that is toxic, antifeedant, and repellent to the yellow fever mosquito Aedes aegypti. ( 29425195 )
2018
33
Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Preliminary Report. ( 29443626 )
2018
34
Persistence of Yellow fever virus outside the Amazon Basin, causing epidemics in Southeast Brazil, from 2016 to 2018. ( 29864115 )
2018
35
Adaptive Diversification between Yellow Fever Virus West African and South American Lineages: A Genome-Wide Study. ( 28044043 )
2017
36
Synthesis and structure-activity relationships of carbohydrazides and 1,3,4-oxadiazole derivatives bearing imidazolidine moiety against the yellow fever and dengue vector, Aedes aegypti. ( 28869331 )
2017
37
Addressing a Yellow Fever Vaccine Shortage - United States, 2016-2017. ( 28472025 )
2017
38
Yellow fever in Africa and the Americas, 2016. ( 28799735 )
2017
39
Yellow fever vaccination: estimating coverage. ( 28822782 )
2017
40
Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination. ( 28386132 )
2017
41
What to expect from the 2017 yellow fever outbreak in Brazil? ( 28423092 )
2017
42
Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults. ( 28380113 )
2017
43
Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease. ( 28366605 )
2017
44
Update: Temporary Total Depletion of U.S. Licensed Yellow Fever Vaccine for Civilian Travelers Addressed by Investigational New Drug Use of Imported Stamaril Vaccine. ( 28749924 )
2017
45
The Yellow Fever Vaccine Misadventure of 1942. ( 28492447 )
2017
46
Yellow fever from Angola and Congo: a storm gathers. ( 28424031 )
2017
47
Not a polar island: yellow fever, Spanish medical research, and the struggle for scientific and political hegemony in late nineteenth century Cuba. ( 29412261 )
2017
48
Yellow Fever Outbreak - Kongo Central Province, Democratic Republic of the Congo, August 2016. ( 28358796 )
2017
49
The first detected airline introductions of yellow fever mosquitoes (Aedes aegypti) to Europe, at Schiphol International airport, the Netherlands. ( 29221490 )
2017
50
Efficacy of Some Wearable Devices Compared with Spray-On Insect Repellents for the Yellow Fever Mosquito, Aedes aegypti (L.) (Diptera: Culicidae). ( 28423421 )
2017

Variations for Yellow Fever

Expression for Yellow Fever

Search GEO for disease gene expression data for Yellow Fever.

Pathways for Yellow Fever

Pathways related to Yellow Fever according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 CCL5 CCR5 FGA IL17A IL1A IL5
2
Show member pathways
13.17 CCL5 CCR5 IL17A IL1A IL5 RAF1
3
Show member pathways
12.76 CCL5 CCR5 FGA IL17A IL1A IL5
4
Show member pathways
12.3 IL17A IL1A IL5 IRF7 OAS1 RAF1
5 12.25 CCL5 IL17A IRF7 OAS1 RSAD2 TLR9
6
Show member pathways
12.13 CCR5 IL17A IL1A IL5 RAF1
7 11.98 IL1A RAF1 TLR9
8
Show member pathways
11.91 CCL5 EIF2AK4 IL1A IRF7 OAS1 RAF1
9 11.85 EIF2AK4 IRF7 OAS1 RAF1
10
Show member pathways
11.84 CCL5 IL17A IL1A IL5
11
Show member pathways
11.8 IL1A IL5 RAF1 TLR9
12 11.71 IL1A IRF7 RAF1
13 11.63 CCL5 IL17A IL1A
14 11.32 CCL5 CCR5 IL1A
15 11.07 IL17A IL5
16 11.03 IL1A IL5
17
Show member pathways
10.9 IRF7 OAS1

GO Terms for Yellow Fever

Cellular components related to Yellow Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 CCL5 F10 FGA IL17A IL1A IL5

Biological processes related to Yellow Fever according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.89 FGA IRF7 OAS1 RSAD2 TLR9
2 regulation of signaling receptor activity GO:0010469 9.86 CCL5 IL17A IL1A IL5
3 viral process GO:0016032 9.84 CCR5 EIF2AK4 IRF7 RSAD2
4 MAPK cascade GO:0000165 9.81 CCL5 CCR5 IL5 RAF1
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.78 CCL5 FGA IL1A RAF1
6 cytokine-mediated signaling pathway GO:0019221 9.77 CCL5 CCR5 IL17A IL1A IL5
7 defense response to virus GO:0051607 9.73 EIF2AK4 IRF7 OAS1 RSAD2
8 immune system process GO:0002376 9.73 EIF2AK4 FGA IRF7 OAS1 RSAD2 TLR9
9 type I interferon signaling pathway GO:0060337 9.63 IRF7 OAS1 RSAD2
10 immune response GO:0006955 9.63 CCL5 CCR5 IL17A IL1A IL5 OAS1
11 response to virus GO:0009615 9.62 CCL5 IRF7 OAS1 RSAD2
12 negative regulation of viral genome replication GO:0045071 9.58 CCL5 OAS1 RSAD2
13 positive regulation of interferon-beta production GO:0032728 9.57 IRF7 TLR9
14 positive regulation of JAK-STAT cascade GO:0046427 9.55 CCL5 IL5
15 dendritic cell chemotaxis GO:0002407 9.52 CCL5 CCR5
16 inflammatory response GO:0006954 9.43 CCL5 CCR5 IL17A IL1A IL5 TLR9
17 negative regulation of macrophage apoptotic process GO:2000110 8.8 CCL5 CCR5 IRF7

Molecular functions related to Yellow Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.47 CCL5 CCR5 EIF2AK4 F10 FGA IL17A
2 phosphatidylinositol phospholipase C activity GO:0004435 9.26 CCL5 CCR5
3 cytokine activity GO:0005125 9.26 CCL5 IL17A IL1A IL5
4 interleukin-1 receptor binding GO:0005149 9.16 IL1A TLR9

Sources for Yellow Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....